目的 探讨西黄胶囊联合莫西沙星治疗慢性盆腔炎的临床疗效。方法 回顾性选取2022年3月—2024年1月北京市怀柔区妇幼保健院中医科收治的76例慢性盆腔炎患者，根据用药方案差异将患者分为对照组（38例）和治疗组（38例）。对照组口服盐酸莫西沙星片，0.4 g/次，每日1次。在对照组基础上，治疗组口服西黄胶囊，8粒/次，每日2次。1个疗程为7 d，两组治疗3个疗程。观察治疗疗效和临床症状缓解时间，比较两组治疗前后简明健康生活质量状况调查表评分（SF-36）、女性性功能指数评分（FSFI）、盆腔包块直径大小、白细胞介素1β（IL-1β）、基质金属蛋白酶-2（MMP-2）、细胞间黏附分子-1（ICAM-1）、血管内皮生长因子（VEGF）水平。结果 治疗21 d后，治疗组总有效率是94.74%，显著高于对照组的76.32%（P＜0.05）。治疗21 d后，治疗组下腹坠痛缓解时间、神疲乏力缓解时间、白带增多缓解时间、腰骶酸痛缓解时间均显著短于对照组（P＜0.05）。治疗后，两组患者FSFI评分、SF-36评分显著升高，而盆腔包块直径明显缩小（P＜0.05）；治疗后，与对照组对比，治疗组FSFI评分、SF-36评分均高于对照组，盆腔包块直经小于对照组（P＜0.05）。治疗后，两组MMP-2、ICAM-1、IL-1β、VEGF水平均显著降低（P＜0.05）；治疗后，与对照组对比，治疗组MMP-2、ICAM-1、IL-1β、VEGF水平均更低（P＜0.05）。结论 西黄胶囊与莫西沙星协同治疗疗效显著，能缩短患者症状缓解时间，缩小盆腔包块直径，减弱机体炎性反应，有效提升生活质量，值得临床借鉴。

Objective To investigate the therapeutic effect of Xihuang Capsules combined with moxifloxacin in treatment of chronic pelvic inflammatory disease. Methods 76 Patients with chronic pelvic inflammatory disease admitted to the Department of Traditional Chinese Medicine of Huairou District Maternal and Child Health Hospital of Beijing from March 2022 to January 2024 were retrospectively selected. According to the difference of medication regimen, the patients were divided into control (38 cases) and treatment (38 cases). Patients in control were po administered with Moxifloxacin Hydrochloride Tablets, 0.4 g/time, once daily. Patients in treatment were po administered with Xihuang Capsules on the basis of the control, 8 grains/time, twice daily. 7 Days was a course of treatment, and patients in both were treated for 3 consecutive courses. The therapeutic effect and clinical symptom remission time were observed. The levels of IL-1β, MMP-2, ICAM-1, and VEGF were compared between two before and after treatment. Results After 21 d of treatment, the total effective rate of the treatment was 94.74%, which was significantly higher than that of the control (76.32%, P < 0.05). After 21 d of treatment, the relief time of lower abdominal pain, fatigue, leucorrhea and lumbosacral pain in the treatment were significantly shorter than those in the control (P< 0.05). After treatment, FSFI scores and SF-36 scores were significantly increased in both, but the diameter of pelvic mass was significantly reduced (P < 0.05). After treatment, compared with the control, FSFI score and SF-36 score in the treatment were higher than those in the control, and the direct length of pelvic mass was lower than that in the control group (P < 0.05). After treatment, the levels of MMP-2, ICAM-1, IL-1β and VEGF were significantly decreased in both (P < 0.05). After treatment, the levels of MMP-2, ICAM-1, IL-1β and VEGF in the treatment were lower than those in the control (P < 0.05). Conclusion Xihuang Capsules combined with moxifloxacin has a good clinical effect in treatment of chronic pelvic inflammatory disease, and can shorten the symptom relief time of patients, reduce the diameter of pelvic mass and the inflammatory response of the body.

R984

首都医科附属北京妇产医院怀柔妇幼保健院东方育苗科研基金（FYDY2023-04）